Mechanistically, the abnormal activation of USP32 contributes to cancer cell proliferation, invasion and drug resistance via regulating the expression of downstream factors such as SMAD, SHMT2, SLC35F2 and FDFT1 [17]. The gene discussed is USP32; the disease is cancer.